What is B. Riley’s Forecast for MDGL Q1 Earnings?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Equities research analysts at B. Riley issued their Q1 2025 earnings estimates for shares of Madrigal Pharmaceuticals in a note issued to investors on Monday, November 4th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings of ($3.34) per share for the quarter. B. Riley currently has a “Neutral” rating and a $236.00 target price on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($25.19) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q3 2025 earnings at ($2.86) EPS and Q4 2025 earnings at ($2.46) EPS.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) EPS for the quarter, beating the consensus estimate of ($6.94) by $2.02. The business had revenue of $62.18 million for the quarter, compared to the consensus estimate of $34.60 million. During the same quarter in the previous year, the firm posted ($5.34) EPS.

Other equities analysts have also recently issued research reports about the company. Oppenheimer reduced their target price on Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. HC Wainwright restated a “buy” rating and set a $390.00 price objective on shares of Madrigal Pharmaceuticals in a report on Tuesday, October 22nd. Evercore ISI lowered their target price on shares of Madrigal Pharmaceuticals from $405.00 to $360.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. JMP Securities lifted their price target on shares of Madrigal Pharmaceuticals from $381.00 to $385.00 and gave the stock a “market outperform” rating in a research report on Tuesday, July 16th. Finally, UBS Group upped their price objective on shares of Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, Madrigal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $347.33.

Madrigal Pharmaceuticals Stock Up 4.9 %

Shares of Madrigal Pharmaceuticals stock opened at $354.85 on Wednesday. The business has a fifty day simple moving average of $234.44 and a 200 day simple moving average of $245.87. The stock has a market cap of $7.74 billion, a PE ratio of -14.15 and a beta of -0.46. The company has a quick ratio of 5.93, a current ratio of 5.98 and a debt-to-equity ratio of 0.15. Madrigal Pharmaceuticals has a 12 month low of $133.99 and a 12 month high of $368.29.

Institutional Trading of Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Oppenheimer Asset Management Inc. increased its position in shares of Madrigal Pharmaceuticals by 2.1% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 1,507 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 31 shares during the last quarter. Signaturefd LLC increased its holdings in Madrigal Pharmaceuticals by 36.8% during the second quarter. Signaturefd LLC now owns 145 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 39 shares during the last quarter. Victory Capital Management Inc. raised its position in Madrigal Pharmaceuticals by 1.8% during the third quarter. Victory Capital Management Inc. now owns 2,292 shares of the biopharmaceutical company’s stock worth $486,000 after acquiring an additional 40 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Madrigal Pharmaceuticals by 47.6% in the third quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 68 shares during the last quarter. Finally, Creative Planning grew its position in shares of Madrigal Pharmaceuticals by 2.7% in the 3rd quarter. Creative Planning now owns 3,299 shares of the biopharmaceutical company’s stock valued at $700,000 after acquiring an additional 87 shares during the period. Institutional investors own 98.50% of the company’s stock.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, CEO William John Sibold sold 6,363 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $243.83, for a total transaction of $1,551,490.29. Following the completion of the transaction, the chief executive officer now directly owns 55,887 shares of the company’s stock, valued at $13,626,927.21. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Madrigal Pharmaceuticals news, Director Richard S. Levy sold 5,000 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $300.94, for a total transaction of $1,504,700.00. Following the sale, the director now directly owns 11,012 shares of the company’s stock, valued at $3,313,951.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO William John Sibold sold 6,363 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $243.83, for a total value of $1,551,490.29. Following the completion of the transaction, the chief executive officer now owns 55,887 shares of the company’s stock, valued at $13,626,927.21. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 22.80% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.